Sanjivani Paranteral Ltd Reports 41.3% YoY Revenue Growth in Q4 FY25, PAT Up 74.4%

Sanjivani Paranteral Ltd, a Mumbai-based pharmaceutical company, has reported its financial results for the quarter and year ended 31 March 2025. The company's revenue from operations grew by 41.3% YoY to INR 181.8 mn in Q4 FY25. The EBITDA margin stood at 16.8%, down 42bps YoY. The Profit After Tax (PAT) stood at INR 21.9 mn, up 74.4% YoY. The company's total income for FY25 was INR 713.1 mn, a 30.1% YoY increase. The injectables segment contributed INR 130.8 mn to the total revenue, up 16.1% YoY. Exports accounted for 27.5% of the total revenue, while domestic sales made up 72.5%. The core markets of CIS, Middle East & Africa, and Latin America accounted for 72.5% of the total revenue.